Respiri (ASX:RSH) announces significant reduction in healthcare events

Respiri Limited (ASX:RSH; OTCQB:RSHUF) has reported a remarkable reduction in hospitalizations and emergency room visits through its patient programs. The company's programs have shown a 56% reduction in re-hospitalizations and a 47% reduction in emergency room visits, leading to discussions with new and existing clients. Respiri has also increased the per patient per month (pppm) revenues for existing Ceras clients from $49 to $74 after only 3 months of engagement. These results have accelerated discussions with potential clients, particularly those with risk share/value-based payor/insurer contracts.

Executive Commentary on Respiri's Program Results

Mr Mikel, Respiri CEO, stated, 'Clearly demonstrating that our programs deliver better outcomes for patients resulting in reduced costs for our clients, is another significant step forward for Respiri. This is a particularly compelling narrative for our clients engaged in risk share contracts, where optimizing investments and reducing costs are key. Additionally, our fee for service clients clearly demonstrate that our programs improve patients' well-being. This continues to build our reputation in the USA which will continue to fuel growth which excite our team.'

Summary of Respiri's ASX Announcement

Respiri's programs have shown a substantial reduction in healthcare events, leading to discussions with new and existing clients, particularly those with risk share/value-based payor/insurer contracts. The company has also increased the per patient per month revenues for existing Ceras clients and expanded its program with New York Cancer & Blood, expecting significant annualized revenues. The success of the program with University of Alabama Hospital system has led to an expansion of services to the University's second healthcare system. Respiri's CEO highlighted the improved outcomes for patients and reduced costs for clients, emphasizing the company's growing reputation in the USA. The company's innovative approach and strategic partnerships position it at the forefront of chronic disease management, ensuring consistent and effective healthcare delivery.